Log In Sign up
The largest database of trusted experimental protocols
> Physiology > Clinical Attribute > Diastole

Diastole

Diastole is the phase of the cardiac cycle when the heart's ventricles relax and fill with blood.
During this period, the heart's chambers dilate, allowing for the efficient filling of the ventricles prior to the next contraction.
Understanding the mechanisms and characteristics of diastole is crucial for the study and management of various cardiovascular conditions, such as heart failure, hypertension, and valvular heart diseases.
Optimal protocols and analysis tools, like PubCompare.ai, can help researchers enhance the reproducibility and accuracy of diastolic function assessments, leading to improved patient outcomes and advancements in the field of cardiology.

Most cited protocols related to «Diastole»

1
Validating Heart Failure Algorithms in Claims Data
The methods and details for Mini-Sentinel systematic reviews have been described elsewhere. (Carnahan, 2011) The specific search strategy for the HF review can be found in the full report which can be found at http://mini-sentinel.org/foundational_activities/related_projects/default.aspx. Briefly, PubMed and Iowa Drug Information Service (IDIS) searches were performed to identify studies published between 1990 and June, 2010 that evaluated the validity of algorithms for identifying HF in administrative and claims data. Certain search terms related to administrative and claims data are described in detail by Carnahan (2011) and were included in all Mini-Sentinel systematic review searches. In addition to these key words, the following PubMed search terms were used for the HF report: “Heart Failure” [Mesh]. In addition, the IDIS search included specification of the following terms: 428. (NOTE: 428. includes: FAILURE, HEART NEC; FAILURE, HEART, CONGESTIVE; FAILURE, HEART, LEFT; FAILURE, HEART, SYSTOLIC; and FAILURE, HEART, DIASTOLIC). Mini-Sentinel collaborators were requested to identify any published or unpublished work that validated an algorithm to identify HF in administrative and claims data.
Two Mini-Sentinel investigators reviewed all abstracts identified through the initial PubMed and IDIS searches, identifying potentially relevant articles based on predefined criteria. Articles were excluded from full text review if they did not study heart failure, were not based on an administrative or claims dataset, or included a data source outside of the U.S. or Canada. Articles identified for full review by either investigator were retrieved and reviewed by two investigators. In the event of disagreement between reviewers, the full article was reviewed.
Selected articles were reviewed with the goal of identifying validated algorithms for identifying HF in administrative and claims data. Investigators also identified citations from the article’s reference sections if they were cited as studies validating an algorithm for HF or were otherwise deemed to be potentially relevant. Articles identified through reference sections were reviewed in a similar manner. A single investigator abstracted information for each study which included the following: database, coding system (e.g., ICD-9 codes), study population (including information on inpatient and outpatient composition of the sample), time period, incident or prevalent case, specific algorithm used to identify cases of HF, adjudication criteria (e.g., Framingham criteria), validation process (e.g., medical record review), and validation statistics. The second reviewer confirmed the accuracy of abstracted information.
Cohen’s kappa for agreement was calculated between reviewers for the inclusion versus exclusion of abstracts and full-text text articles.
Saczynski J.S., Andrade S.E., Harrold L.R., Tjia J., Cutrona S.L., Dodd K.S., Goldberg R.J, & Gurwitz J.H. (2012). Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative and Claims Data: Heart Failure. Pharmacoepidemiology and drug safety, 21(0 1), 10.1002/pds.2313.
Publication 2012
Congestive Heart Failure Diastole Drug Information Services Heart Inpatient Outpatients Systole
2
Cardiac MRI Measurement of LV Mass and Volume

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
Antihypertensive Agents Body Size Body Surface Area Dental Caries Diabetes Mellitus Diastole Endocardium Epistropheus Glucose Heart Heart Ventricle High Blood Pressures Hypoglycemic Agents Left Ventricles Males Myocardium Obesity Papillary Muscles Woman
3
Comparative Analysis of Blood Pressure Measurement Methods
Several BP measurement methods are now available. The main methods include catheterization, auscultation, oscillometry, volume clamping, and tonometry.
Catheterization is the gold standard method [6 (link)]. This method measures instantaneous BP by placing a strain gauge in fluid contact with blood at any arterial site (e.g., radial artery, aorta). However, the method is invasive.
Auscultation, oscillometry, and volume clamping are noninvasive methods. These methods employ an inflatable cuff.
Auscultation is the standard clinical method [7 (link)]. This method measures systolic and diastolic BP by occluding an artery with a cuff and detecting the Korotkoff sounds using a stethoscope and manometer during cuff deflation. The first sound indicates the initiation of turbulent flow and thus systolic BP, while the fifth sound is silent and indicates the renewal of laminar flow and thus diastolic BP.
Oscillometry is the most popular non-invasive, automatic method [8 (link), 9 (link)]. This method measures mean, diastolic, and systolic BP by also using a cuff but with a pressure sensor inside it. The measured cuff pressure not only rises and falls with cuff inflation and deflation but also shows tiny oscillations indicating the pulsatile blood volume in the artery. The amplitude of these oscillations varies with the applied cuff pressure, as the arterial elasticity is nonlinear. The BP values are estimated from the varying oscillation amplitudes using the empirical fixed-ratios principle. When evaluated against auscultation using an Association for the Advancement of Medical Instrumentation (AAMI) protocol, some oscillometric devices achieve BP errors within the AAMI limits of 5 mmHg bias and 8 mmHg precision [10 ]. However, oscillometry is unreliable in subjects with certain conditions such as atrial fibrillation, stiff arteries, and pre-eclampsia [11 ].
Volume clamping is a non-invasive, automatic method used in research [12 (link), 13 ]. This method measures instantaneous (finger) BP by using a cuff and a photoplethysmography (PPG) sensor to measure the blood volume (see Section V.A). The blood volume at zero transmural pressure is estimated via oscillometry. The cuff pressure is then continually varied to maintain this blood volume throughout the cardiac cycle via a fast servo-control system. The applied cuff pressure may thus equal BP. Volume clamping devices also achieve BP errors within AAMI limits when evaluated against auscultation and near AAMI limits when evaluated against radial artery catheterization [14 (link)].
However, cuff use has several drawbacks. In particular, cuffs are cumbersome and time consuming to use, disruptive during ambulatory monitoring, especially while sleeping, and do not readily extend to low resources settings.
Tonometry is another non-invasive method used in research that, in theory, does not require an inflatable cuff [15 , 16 ]. This method measures instantaneous BP by pressing a manometer-tipped probe on an artery. The probe must flatten or applanate the artery so that its wall tension is perpendicular to the probe. However, manual and automatic applanation have proven difficult. As a result, in practice, the measured waveform has been routinely calibrated with cuff BP whenever a BP change is anticipated [17 (link)].
In sum, the existing BP measurement methods are invasive, manual, or require a cuff. So, none are suitable for ubiquitous (i.e., ultra-convenient, unobtrusive, and low cost) monitoring.
Mukkamala R., Hahn J.O., Inan O.T., Mestha L.K., Kim C.S., Töreyin H, & Kyal S. (2015). Towards Ubiquitous Blood Pressure Monitoring via Pulse Transit Time: Theory and Practice. IEEE transactions on bio-medical engineering, 62(8), 1879-1901.
Publication 2015
Aorta Arteries Arteries, Radial Atrial Fibrillation Auscultation BLOOD Blood Pressure Blood Volume Cardiac Volume Catheterization Clinical Protocols Diastole Elasticity Fingers Gold Manometry Medical Devices Oscillometry Photoplethysmography Pre-Eclampsia Pressure Pressure, Diastolic Sound Stethoscopes Strains Systole Systolic Pressure Tonometry
4
Measuring Drosophila Heart Tube Contractility
In intact flies, the edges of the heart tube are typically obscured by both the pigmented cuticle and abdominal fat bodies. However, in the semi-intact preparation, where some fat cells can be removed, the heart tube edges are usually visible in the third abdominal segment. Markers corresponding to the upper and lower edges of the heart tube can be placed in single movie frames directly on the heart edge (Figure 1, A and B). Movies of beating hearts can be advanced manually to identify frames where maximal contraction and relaxation occur; given average frame rates of 130 fps, this determination is extremely accurate. Because the heart tube is one cell-layer thick, it is usually not possible to resolve an inner and an outer edge. Diastolic and systolic diameters obtained are used to calculate a percent fractional shortening (% FS):
which provides an estimate of the contractility of the heart tube. This calculation assumes that the heart tube dimensions are relatively uniform along its length, which is generally the case for the heart in abdominal segments 3 and 4. It should be emphasized these marks are only used to measure diameters and are not used in the heart movement analysis described in the following sections.
Fink M., Callol-Massot C., Chu A., Ruiz-Lozano P., Belmonte J.C., Giles W., Bodmer R, & Ocorr K. (2009). A new method for detection and quantification of heartbeat parameters in Drosophila, zebrafish, and embryonic mouse hearts. BioTechniques, 46(2), 101-113.
Publication 2009
Abdomen Abdominal Fat Adipocytes Cells Diastole Diptera Fat Body Heart Heart Contractility Human Body Movement Reading Frames Systole
5
Meta-analysis of Blood Pressure Reduction
All statistical analyses were done using Stata software. We combined relative risk estimates of disease events from individual trials using a random effects model31 (link) (which avoids assuming that participants in the individual trials in the meta-analysis are sampled from populations in which the intervention has the same quantitative effect). Summary relative risk estimates from blood pressure difference trials were standardised to a blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic, by raising the relative risk estimate in each trial to the appropriate power (10 divided by the observed reduction in systolic blood pressure or 5 divided by the observed reduction in diastolic pressure)—for example, if the relative risk was 0.7 and the reduction in systolic blood pressure was 8 mm Hg, the standardised relative risk estimate was 0.64 (0.71.25, since 10/8=1.25). If reductions in both systolic and diastolic blood pressures were reported (as in most trials), we took the average of the two risk estimates (more strongly predictive than either alone25 (link)). As the reduction in blood pressure was not reported in most trials of people with a history of CHD, we estimated the average reduction from the average blood pressure before treatment and the average drug dose (as a multiple of standard dose32 (link)
33 ), using results from a meta-analysis in which the effect of pretreatment blood pressure and dose on blood pressure reduction was quantified.32 (link) The estimated blood pressure reduction was 5.9 mm Hg systolic and 3.1 mm Hg diastolic, close to the median reduction in the 27 trials in which blood pressure reduction was reported, which was 6 mm Hg systolic and 3 mm Hg diastolic.
Law M.R., Morris J.K, & Wald N.J. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. The BMJ, 338, b1665.
Publication 2009
Blood Pressure Diastole Drug Tapering Pharmaceutical Preparations Population Group Pressure, Diastolic Systole Systolic Pressure

Most recents protocols related to «Diastole»

1
Catheter-Based Renal Neuromodulation for Hypertension
Not available on PMC !

Example 2

Example 2 describes the outcome of catheter-based renal neuromodulation on human patients diagnosed with hypertension. Patients selected having a baseline systolic blood pressure of 160 mm Hg or more (≥150 mm Hg for patients with type 2 diabetes) and taking three or more antihypertensive drugs, were randomly allocated into two groups: 51 assessed in a control group (antihypertensive drugs only) and 49 assessed in a treated group (undergone renal neuromodulation and antihypertensive drugs).

Patients in both groups were assessed at 6 months. Office-based blood pressure measurements in the treated group were reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0.0001), whereas they did not differ from baseline in the control group (change of I/O mm Hg, baseline of 178/97 mm Hg, p=0.77 systolic and p=0.83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0.0001). At 6 months, 41 (84%) of 49 patients who underwent renal neuromodulation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 control patients (p<0.0001).

US11865343B2. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation (2024-01-09). Medtronic Ireland Manufacturing Unlimited Company [IE]. Inventors: Marcia Gallagher [IE], Douglas A. Hettrick [US].
Patent 2024
Antihypertensive Agents BLOOD Blood Pressure Catheters Determination, Blood Pressure Diabetes Mellitus, Non-Insulin-Dependent Diastole High Blood Pressures Homo sapiens Kidney Patients Post-Traumatic Stress Disorder Pressure Systole Systolic Pressure
2
Echocardiography Characterization of Left Ventricular Diastolic Dysfunction
Echocardiography was conducted by experienced sonographers using the Vivid E95 ultrasound system (GE Vingmed Ultrasound, Horten, Norway). Images in cine loop format were analyzed offline using the EchoPAC software (EchoPAC 204, GE Vingmed Ultrasound). All indices were measured according to ASE guidelines [15 , 16 (link)]. Pulse Doppler imaging was used to measure the mitral valve peak early (E) and late (A) diastolic velocities, E/A ratio, and LV isovolumic relaxation time (IVRT). LVEF was calculated using the biplane Simpson’s method. LV global longitudinal strain (GLS) was defined as the average peak longitudinal strains obtained from three apical views [17 (link)]. Peak strain dispersion (PSD) was the standard deviation of the time-to-peak longitudinal strains for all segments [18 (link)].
According to the criteria of ASE [19 (link)], the cut-offs for abnormal LV diastolic performance were, as follows: (1) septal mitral annular e′ velocity of < 7 cm/s or lateral mitral annular e′ velocity of < 10 cm/s; (2) average E/e′ ratio of > 14; (3) LAVI of > 34 ml/m2; (4) peak tricuspid regurgitation velocity of > 2.8 m/s. The patients were diagnosed, as follows: LVDD, when > 50% of the indexes met the above criteria; indeterminate LVDD, when merely 50% of the criteria were positive; with risk of developing LVDD but not LVDD yet, when < 50% of the indexes met the above criteria [19 (link)]. For patients with LVDD, the severity of LVDD was defined according to the 2016 EACVI criteria [19 (link), 20 (link)], as follows: mild, when E/A ≤ 0.8 and E ≤ 50 cm/s or ≥ 2 negative criteria (LAVI > 34 ml/m2, average E/e’ > 14, or TR > 2.8 m/s); moderate, when E/A ≤ 0.8 and E > 50 cm/s or 0.8 < E/A < 2 + ≥ 2 positive criteria (LAVI > 34 ml/m2, average E/e’ > 14, or TR > 2.8 m/s); severe, when E/A ≥ 2. Based on the above two criteria, the patients in the present study were categorized into three subgroups: patients with risks for LVDD but without LVDD (n = 237), patients with indeterminate or mild LVDD (n = 113), and patients with moderate or severe LVDD (n = 98). Among these patients, three patients met the criteria for mild LVDD, and seven patients met the criteria for severe LVDD.
Guo Y., Wang X., Yang C.G., Meng X.Y., Li Y., Xia C.X., Xu T., Weng S.X., Zhong Y., Zhang R.S, & Wang F. (2023). Noninvasive assessment of myocardial work during left ventricular isovolumic relaxation in patients with diastolic dysfunction. BMC Cardiovascular Disorders, 23, 129.
Publication 2023
Diastole Echocardiography Mitral Valve Patients Pulse Rate Strains Tricuspid Valve Insufficiency Ultrasonography
3
Doppler Phonolyser: Innovative Heart Sound Analysis
The Doppler Phonolyser AD0302 (Bu-Ali Research Institute, Mashhad, Iran, www.phonolyser.com) is a “smart heart sound analyzer based on the Doppler Effect” used to diagnose congenital and structural diseases of the heart (Fig. 1). Doppler, sound and electrocardiogram signals are displayed on the monitor of the device online synchronously. By this technique, the physician can determine the time of the murmurs. This device separates normal sound from a murmur by analyzing the heart sound. The physician can determine the time of the murmurs using the synchronization of the Doppler signal and ECG. The lack of influence of ambient noise and use of the Doppler Effect make the device more efficient in detecting cardiac murmurs. The Doppler Phonolyser overcomes two of the following technical issues that have long been of interest to physicians:

The Doppler Phonolyser shows a low gradient difference that cannot be heard through a stethoscope.

Cases such as ambient sounds, patient breathing, obesity and slimming and transpiration do not affect Doppler Phonolyser's function.

Doppler Phonolyser device

Phonolyser’s software is an AI-based software that detects abnormalities in the heart’s blood flow. It shows 3 graphs (Fig. 2).

Doppler Phonolyser shows 3 graphs. the top graph shows the electrocardiogram signal, the middle graph shows the sound of the heart, and the bottom graph shows Doppler results

The top graph is ECG that is used to find the systole and diastole time of the heart. The middle one shows the sound of the heart, and the bottom graph shows doppler results. If the heart has a normal structure the Doppler graph will be green and if due to congenital heart diseases the blood flow has any turbulence, the graph’s color will be changed to red.
The technical parameters are shown in Table 5.

Technical parameters of Doppler Phonolyser

ParametersDescription
ProbUltrasound 2 MHz
Device diameters275 × 204x97mm
power

100–240 V

50–60 Hz

single-phase supply

LCD

5 inches

resolution: 800 × 480

Printer

Thermal printer

Paper width: 57.5 ± 0.5 mm

paper roll diameter: 50 mm Max

Method(s) of sterilizationBy methods validated and described by the manufacture
Suitability for use in an oxygen rich environmentNon-inclusion
Mode of operationContinuous operation
Temperature + 10^C–+ 40^C
Humidity < 80%
Pressure86 kPa–106 kPa
Protection against harmful ingress of water or particulate matterNo production (IP00)
Khalilian M.R., Safari M., Hajipour M., Rahmani K., Safari M., Ahmadpour M.H, & Tahouri T. (2023). Evaluation of the heart sounds in children using a Doppler Phonolyser. BioMedical Engineering OnLine, 22, 24.
Publication 2023
Blood Circulation Congenital Heart Defects Diagnosis Diastole Doppler Effect Hearing Heart Heart Diseases Heart Sounds Medical Devices Obesity Oxygen Patients Physicians Sound Stethoscopes Systole
4
Cardiac Magnetic Resonance Imaging for LV Function
All participants were scheduled to have CMR-LGE examination just before each CPET. CMR-LGE examination involved a 3.0-Tesla Skyra scanner (Siemens Medical Systems, Erlangen, Germany) operating on the VD13 platform with a 32-channel phased-array receiver body coil. Short-axis (contiguous 8-mm-thick slices) and standard long-axis view (2-, 3- and 4-chamber views) cine images were obtained by steady-state free precession (SSFP) cine imaging with the following parameters: repetition time, 45 ms; echo time, 1.4 ms; matrix, 256 × 256; and field of view, 34 to 40 cm. LV geometry as well as functions, including LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), resting CO (COrest), LVEF, LV mass, and left ventricle wall motion (LVWMS) were determined using SSFP cine imaging. The lower the LVWMS is, the better the LV contractility [28 (link)].
Quantitative parametric images of myocardial extracellular volume (ECV) fractions were acquired from longitudinal relaxation time (T1) mapping in short-axis slices before (pre) and after (post) contrast medium enhancement. The ECV was estimated by the following equation: ECV=(1-hematocrit)(1T1myopost-1T1myopre)(1T1bloodpost-1(T1bloodpre)
The CMR-LGE system determines the T1 in each myocardial segment. Myocardial fibrosis was estimated with a modified Look-Locker inversion-recovery (MOLLI) sequence [15 (link)] acquired during the end-expiratory phase in the basal, middle and apical LV myocardial segments at short-axes before (T1myo pre) and approximately 15 to 20 min after (T1myo post) a 0.1 mmol/kg intravenous dose of gadolinium-DOTA (gadoterate meglumine, Dotarem, Guerbet S.A., France). The ECV value was further normalized by the blood T1 mapping image before (T1blood pre) and after (T1blood post) enhancement in the corresponding short-axis slices. The basal slice (Base), mid-cavity slice (Middle), and apical slice (Apex) of LV myocardial segments [29 (link)] were drawn along the epicardial and endocardial surfaces on matched pre- and post-contrast MOLLI images to identify the myocardium for ECV analysis.
Hsu C.C., Wang J.S., Shyu Y.C., Fu T.C., Juan Y.H., Yuan S.S., Wang C.H., Yeh C.H., Liao P.C., Wu H.Y, & Hsu P.H. (2023). Hypermethylation of ACADVL is involved in the high-intensity interval training-associated reduction of cardiac fibrosis in heart failure patients. Journal of Translational Medicine, 21, 187.
Publication 2023
BLOOD Cardiovascular System Clostridium perfringens epsilon-toxin Dental Caries Diastole Dotarem ECHO protocol Endocardium Epistropheus Exhaling Fibrosis Gadolinium gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate gadoterate meglumine Human Body Inversion, Chromosome Left Ventricles Muscle Contraction Myocardium Sequence Inversion Systole Volumes, Packed Erythrocyte
5
Delayed-Onset Postpartum Preeclampsia Retrospective Study
We conducted a retrospective cohort study of all women readmitted to Meir Medical Center, from January 2014 through March 2020, with new delayed-onset of postpartum preeclampsia. Delayed-onset postpartum preeclampsia was defined as a new diagnosis of preeclampsia that occurred 48 h to 6 weeks postpartum. Preeclampsia was defined according to the American College of Obstetricians and Gynecologists criteria as blood pressure of 140 mm Hg systolic or 90 mm Hg diastolic or higher on two or more occasions more than 6 h apart, accompanied by proteinuria or end organ dysfunction, or blood pressure 160 mm Hg systolic or 110 mmHg diastolic or higher [9 (link)]. Excluded from the study women with prior diagnosis of preeclampsia, gestational hypertension, or chronic hypertension as well as women with prior chronic diseases.
The control group included randomly recruited healthy parturients with uncomplicated pregnancies, who came, during 2020, to the hospital for a routine screening hearing test for their newborns in the neonatal clinic, during postpartum period, on days 2–11.
.Data were collected by electronic medical record review and included: maternal age, gravity and parity, characteristics of current pregnancy (gestational age at delivery, mode of delivery, neonatal birth weight) and hemoglobin level on the day of labor. The postpartum hospitalization data included postpartum day of readmission and clinical features on presentation including pulse rate (beat per minute, bpm), blood pressure and serum laboratory values of liver function and platelet count. Pulse rate (bpm) and blood pressure of the control group were measured after at least 10 min of rest in a sitting position.
The study was approved by the Meir Medical Center Institutional Review Board on 17th March 2020, number MMC-0048–20. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was not obtained from subjects due to the study nature.
Ravid D., Ovadia M., Asali A., Nisim S., Gershnabel S.F., Biron-Shental T, & Weitzner O. (2023). Changes in maternal heart rate in delayed post-partum preeclampsia. BMC Women's Health, 23, 99.
Publication 2023
Audiometry Birth Weight Blood Pressure Diagnosis Diastole Disease, Chronic Ethics Committees, Research Gestational Age Gravity Gynecologist Hemoglobin High Blood Pressures Hospitalization Infant, Newborn Liver Obstetric Delivery Obstetrician Obstetric Labor Platelet Counts, Blood Pre-Eclampsia Pregnancy Pulse Rate Serum Systole Transient Hypertension, Pregnancy Woman

Top products related to «Diastole»

1
Vevo 2100 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
2
Vivid 7 by GE Healthcare
Sourced in United States, Norway, United Kingdom, Japan, France, Canada, Germany, Belgium
The Vivid 7 is a high-performance ultrasound system designed for cardiovascular and general imaging applications. It features advanced imaging technologies and versatile capabilities to support comprehensive diagnostic assessments.
3
Vevo 770 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 770 is a high-resolution, real-time, in vivo micro-imaging system designed for small animal research. It employs high-frequency ultrasound technology to produce detailed anatomical and functional images.
4
Vivid e9 by GE Healthcare
Sourced in United States, Norway, Japan, United Kingdom, Germany
The Vivid E9 is a diagnostic ultrasound system developed by GE Healthcare. It is designed to provide high-quality imaging for a wide range of clinical applications.
5
Vevo 2100 imaging system by Fujifilm
Sourced in Canada, United States
The Vevo 2100 Imaging System is a high-resolution ultrasound platform designed for preclinical research applications. It provides real-time, high-quality imaging of small animals and other biological samples.
6
Vevo 2100 system by Fujifilm
Sourced in Canada, United States
The Vevo 2100 system is a high-frequency, high-resolution micro-ultrasound imaging platform designed for preclinical research applications. The system utilizes advanced transducer technology to capture real-time, high-quality images and data from small animal models.
7
Cvi42 by Circle Cardiovascular Imaging
Sourced in Canada, Germany
Cvi42 is a comprehensive cardiovascular imaging and analysis software suite developed by Circle Cardiovascular Imaging. It provides tools for the visualization, quantification, and interpretation of cardiovascular imaging data.
8
Vevo 3100 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 3100 is a high-resolution, real-time micro-imaging system designed for preclinical research. It is capable of producing high-quality images of small animals and other biological samples using ultrasound technology.
9
Sonos 5500 by Philips
Sourced in United States, Germany, Japan, Netherlands, Norway
The Sonos 5500 is a laboratory equipment designed for ultrasound imaging and analysis. It features a high-resolution display and advanced signal processing capabilities. The device is capable of generating and receiving ultrasound signals for a variety of applications in research and diagnostic settings.
10
Matlab by MathWorks
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.

More about "Diastole"

Diastole is the crucial phase of the cardiac cycle when the heart's ventricles relax and fill with blood.
During this period, the heart's chambers dilate, allowing for the efficient filling of the ventricles prior to the next contraction.
Understanding the mechanisms and characteristics of diastole is essential for the study and management of various cardiovascular conditions, such as heart failure, hypertension, and valvular heart diseases.
Optimal protocols and analysis tools, like PubCompare.ai, can help researchers enhance the reproducibility and accuracy of diastolic function assessments, leading to improved patient outcomes and advancements in the field of cardiology.
These tools can be used in conjunction with echocardiographic imaging systems like Vevo 2100, Vivid 7, Vevo 770, Vivid E9, Vevo 2100 Imaging System, Vevo 2100 system, Cvi42, Vevo 3100, Sonos 5500, and analysis software like MATLAB to provide a comprehensive solution for diastole research.
Discover how PubCompare.ai can optimize your diastole research through AI-driven protocol comparison.
Locate the best protocols from literature, pre-prints, and patents, and enhance reproducibility and accuracy with our innovative tool.
Experieince the power of AI-driven analysis to identify the optimal protocols and products for your diastole studies, ultimately contributing to a better understanding of cardiovascular health and improved patient care.